NRBO Stock Overview
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
NeuroBo Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.30 |
52 Week High | US$7.60 |
52 Week Low | US$2.89 |
Beta | -0.43 |
1 Month Change | -18.87% |
3 Month Change | 30.30% |
1 Year Change | -24.30% |
3 Year Change | -99.58% |
5 Year Change | n/a |
Change since IPO | -99.80% |
Recent News & Updates
Recent updates
NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Sep 29Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely
Sep 14NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split
Sep 12NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases
Nov 25NeuroBo on track to post a record gain after announcing a special meeting
Jun 14NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition
Jan 06Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like
Dec 21NeuroBo Pharmaceuticals EPS misses by $0.02
Nov 13Shareholder Returns
NRBO | US Biotechs | US Market | |
---|---|---|---|
7D | 4.6% | -0.5% | 0.6% |
1Y | -24.3% | 9.6% | 29.5% |
Return vs Industry: NRBO underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: NRBO underperformed the US Market which returned 29.8% over the past year.
Price Volatility
NRBO volatility | |
---|---|
NRBO Average Weekly Movement | 23.9% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NRBO's share price has been volatile over the past 3 months.
Volatility Over Time: NRBO's weekly volatility has increased from 16% to 24% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 2 | Hyung-Heon Kim | https://www.neurobopharma.com |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001.
NeuroBo Pharmaceuticals, Inc. Fundamentals Summary
NRBO fundamental statistics | |
---|---|
Market cap | US$21.27m |
Earnings (TTM) | -US$11.83m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs NRBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NRBO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$11.83m |
Earnings | -US$11.83m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.44 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NRBO perform over the long term?
See historical performance and comparison